TRH (Protirelin): molecular data, studies & sources

TRH (Protirelin) is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-10-09 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF): C16H22N6O4
Molecular weight (MW): 362.38 g/mol
PubChem compound ID: 638678
Record title: Protirelin

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 638678 · retrieved 2026-10-09

2D molecular structure for TRH (Protirelin), PubChem CID 638678 — 2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.

Chemical identifiers and source data

IUPAC name: (2S)-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
InChIKey: XNSAINXGIQZQOO-SRVKXCTJSA-N
SMILES: C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N

Machine-readable PubChem source

Identifiers & sequence

PubChem CID: 638678
CAS Registry Number: 24305-27-9via ChemIDplus, EPA DSSTox, FDA GSRS
FDA UNII: 5Y5F15120W
ChEMBL ID: CHEMBL1472
InChIKey: XNSAINXGIQZQOO-SRVKXCTJSA-N
Wikidata: Q12910980

Other names and development codes: ABBOTT-38579 · NSC-760113 · A-38579

Peptide sequence · 3 residues (one-letter code; X marks a residue without a one-letter code)

XHP

Condensed notation with terminal groups and non-standard residues

H-Pyr-His-Pro-NH2

Source: PubChem Biologic Line Notation. A reference sequence for the record, not an analysis of a supplied batch.

CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-09.

Calculated molecular descriptors

Monoisotopic (exact) mass	362.1703 Da
Heavy atoms	26
Hydrogen-bond donors	4
Hydrogen-bond acceptors	5
Rotatable bonds	6
Topological polar surface area	150.3 Å²
Calculated logP (Crippen)	-1.81
Rings	3
Stereocenters	3
Formal charge	0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

US regulatory status & drug development

Drug development record (ChEMBL)

Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.

ChEMBL ID: CHEMBL1472
Modality: Protein / peptide
Highest clinical stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Record name: PROTIRELIN

Mechanism of action

Thyrotropin-releasing hormone receptor agonist · target: Thyrotropin-releasing hormone receptor (TRHR)

Synonyms, codes and trade names

Synonyms and development codes: A-38579 · ABBOTT-38579 · NSC-760113 · Protirelin · SYNTHETIC TRH

Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL1472 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-09

Registered clinical trials

Studies registered on ClinicalTrials.gov that list TRH as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

6 registered studies matched, 3 with results posted on ClinicalTrials.gov.

By highest phase: Phase 3 · 1Phase 2 · 2Phase 1 · 1Not applicable · 2
By registry status: Completed · 4Terminated · 1Withdrawn · 1

Study	Phase · status	Conditions	Sponsor · size
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid CancerNCT04868045 · start 2021-04-27 · primary completion 2023-02-15	Phase 1WithdrawnWhy stopped: Lack of accrual	Thyroid Cancer	Memorial Sloan Kettering Cancer CenterEnrollment not listed
Mechanistic Study of Subclinical Hypothyroidism In the ElderlyNCT02399475 · start 2015-01-01 · primary completion 2019-09-30	Not applicableCompletedResults posted 2021-03-09	Subclinical Hypothyroidism	University of Pennsylvania14 participants
Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related FatigueNCT00790296 · start 2006-12 · primary completion 2010-02	Phase 2TerminatedResults posted 2011-05-03Why stopped: Interim analyses showed statistically and clinically significant results.	Cancer-related Fatigue	UConn Health11 participants
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary AbnormalitiesNCT00054756 · start 2003-02-07 · primary completion 2014-09-26	Phase 2CompletedResults posted 2018-08-08	Healthy · Pituitary Disease · Thyroid Disease	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)96 participants
Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm InfantsNCT00004840 · start 1998-05	Not applicableCompleted	Respiratory Distress Syndrome	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)996 participants
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature DeliveryNCT00004778 · start 1993-08	Phase 3Completed	Respiratory Distress Syndrome	National Center for Research Resources (NCRR)1090 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received TRH, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Review · secondary evidence
Thyrotropin-releasing hormone analogs.
Colson AO, Gershengorn MC · Mini reviews in medicinal chemistry · 2006
PMID 16472189 · DOI: 10.2174/138955706775476019
Review · secondary evidence
Thyrotropin-releasing hormone.
O'Leary R, O'Connor B · Journal of neurochemistry · 1995
PMID 7643125 · DOI: 10.1046/j.1471-4159.1995.65030953.x
Review · secondary evidence
Thyrotropin-releasing hormone.
Jackson IM · The New England journal of medicine · 1982
PMID 6798440 · DOI: 10.1056/NEJM198201213060305
Review · secondary evidence
Protirelin (thyrotropin-releasing hormone) in amyotrophic lateral sclerosis. The role of androgens.
Miller SC, Warnick JE · Archives of neurology · 1989
PMID 2563937 · DOI: 10.1001/archneur.1989.00520390096025
Review · secondary evidence
[Thyrotropin-releasing hormone (TRH)].
Yamada M, Umezawa R · Nihon rinsho. Japanese journal of clinical medicine · 2005
PMID 16149495
Review · secondary evidence
Thyrotropin-releasing hormone.
Pittman JA · Advances in internal medicine · 1974
PMID 4205606
Review · secondary evidence
Orexis, anorexia, and thyrotropin-releasing hormone.
Karydis I, Tolis G · Thyroid : official journal of the American Thyroid Association · 1998
PMID 9827664 · DOI: 10.1089/thy.1998.8.947
Research publication · design requires review
[Thyrotropin releasing hormone].
Sobel R, Liel Y · Harefuah · 1982
PMID 6820788

TRH (Protirelin) supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

PubChem compound record 638678 — chemical identity and structure.
ChEMBL drug record CHEMBL1472 — development stage, mechanism and synonyms.
FDA Global Substance Registration System: UNII 5Y5F15120W — substance identity, names and codes.

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.